Q-omics provides the consensus-scored DLG5 profile across patient tissues and cancer cell-line models. DLG5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DLG5 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, DLG5 RNA expression shows 19,985 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where DLG5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DLG5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DLG5 survival associations across molecular data types. DLG5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (11) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DLG5 RNA expression–survival associations across cancer types. High DLG5 expression shows unfavorable associations in LIHC and COAD, but favorable associations in HNSC, BRCA, LGG and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for DLG5 RNA expression.
This table summarizes DLG5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DLG5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DLG5 shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC, COAD, LUSC and HNSC. The THCA box plot shows higher DLG5 RNA expression in normal versus tumor tissue (log2 FC = −1.174, t-test p < 0.001).
This table shows molecular features associated with DLG5 in patient tissues and cancer cell lines. In patient samples, DLG5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DLG5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
